“Protect from Light” Label Claims in Stability Testing: When and How to Justify Them

Labeling a pharmaceutical product with “Protect from light” is a regulatory and scientific decision driven by the results of photostability testing. This claim directly influences packaging design, distribution conditions, and patient handling instructions. However, applying this label without justification—or omitting it when required—can lead to regulatory scrutiny or product degradation in the field. This expert tutorial outlines the criteria, methodology, and strategic documentation necessary to support “Protect from light” stability claims under ICH Q1B guidelines and global regulatory frameworks.

1. Regulatory Basis for Light Protection Labeling

ICH Q1B Requirements:

• Photostability testing must assess the impact of UV and visible light on the drug substance and product
• Exposure should meet or exceed 1.2 million lux hours (visible) and 200 Wh/m² (UV)
• If significant degradation is observed, protective packaging and labeling must be justified

Global Regulatory References:

• FDA: Light protection is referenced in the Guidance for Industry on Stability Testing
• EMA: Requires evidence-based labeling under EU Variations and QRD templates
• WHO: Includes “Protect from light” in prequalification and GMP labeling guidance

2. When is “Protect from Light” Labeling Required?

Criteria for Inclusion:

• API or drug product shows ≥5% degradation under ICH Q1B conditions
• New degradants appear that exceed identification thresholds per ICH Q3B
• Physical appearance (e.g., color, clarity) changes upon light exposure
• Excipient interaction or packaging failure causes light-induced changes

Risk-Based Exceptions:

• If light-exposed product remains within specification, claim may be optional
• If packaging (e.g., Alu-Alu blister) provides complete light protection, label may not be needed
• Stability data across intended shelf life must support exclusion of label

3. Testing Strategy to Justify Light Protection Labels

Designing a Robust Photostability Study:

• Follow ICH Q1B Option 1 (integrated light source) or Option 2 (separate visible and UV sources)
• Use clear packaging for worst-case assessment
• Include controls stored in the dark

Evaluation Parameters:

• Assay, degradation products (quantitative and qualitative)
• Appearance (color, opacity), pH, and dissolution (for solid dosage forms)
• Spectral analysis for photo-induced changes (e.g., UV shifts, new peaks)

Packaging Comparisons:

• Compare samples stored in intended market packaging vs. light-exposed samples
• Use UV-Vis spectrophotometry to evaluate packaging transmission properties

4. Case Study: Light Labeling Decision for a Nasal Spray

Background:

A corticosteroid nasal spray exhibited loss of potency and appearance changes during photostability testing.

Study Design:

• Exposed solution in clear PET and amber PET containers
• Measured assay, color change, and impurity formation

Results:

• Clear PET: 9% API loss, significant yellowing, new impurity at RT 4.3 min (0.27%)
• Amber PET: 2% API loss, color unchanged, impurity ≤0.05%

Outcome:

• Final container selected: Amber PET with UV-absorbing additives
• Label updated: “Protect from light. Store in the original container.”
• Documentation submitted in CTD Modules 3.2.P.2.5 and 3.2.P.8.3

5. Documentation for Regulatory Submissions

CTD Module Expectations:

• 3.2.S.3.2: Light sensitivity and degradation mechanism for API
• 3.2.P.2.5: Packaging justification and choice rationale
• 3.2.P.5.1: Specifications including photodegradation impurities
• 3.2.P.8.3: Stability summary and label justification

Supporting Data to Include:

• Comparative chromatograms (light-exposed vs. protected)
• Visual and physical observations log
• UV transmission curve of packaging material

6. Labeling Language and Global Harmonization

Standard Phrases:

• “Protect from light”
• “Store in the original container to protect from light”
• “Keep in outer carton to protect from light”

Regional Labeling Guidelines:

• FDA: Uses USP format and requires evidence for stability-related claims
• EMA: Follows QRD template; label claims must be in SPC and PIL
• Canada: Health Canada guidance aligns with ICH Q1B, requires photostability study summary

7. Label Claim Review and Lifecycle Management

Periodic Review:

• Evaluate light protection need during formulation changes, scale-up, or packaging shifts
• Post-marketing stability failures may warrant label change or risk mitigation

Pharmacovigilance and Complaints:

• Monitor field returns and consumer complaints for light-related degradation
• Use as signal to reassess label and packaging effectiveness

8. SOPs and Documentation Templates

Available from Pharma SOP:

• Photostability Testing SOP for Labeling Decisions
• Label Justification Template Based on Photostability Data
• UV Transmission Evaluation Worksheet
• Regulatory Filing Support Template (Label Claim Inclusion)

Further insights and real-world implementation strategies are available at Stability Studies.

Conclusion

“Protect from light” is more than just a label—it is a scientifically and regulatorily significant claim that must be substantiated by robust data. By integrating photostability results with packaging performance and regulatory strategy, pharmaceutical professionals can ensure product integrity throughout the product lifecycle. A proactive and data-driven approach not only secures regulatory approval but also ensures patient safety and product success in global markets.